TrialHaematologica2018

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.

Alan K Burnett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.